The result showed that Nur77 was significantly more lowly expressed in PRAD patients with age below 65 than above 65 (Figure 1C) in the N1 stage than the N0 stage (Figure 1D), and in the T4 stage compared to the T2 and T3 stage (Figure 1E). This evidence concerns the gene NR4A1 and prostate adenocarcinoma.